KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBT (2016 - 2025)

Historic EBT for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's EBT rose 6080.52% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 4489.46%. This contributed to the annual value of -$69.9 million for FY2024, which is 402.06% up from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's EBT is -$7.7 million, which was up 6080.52% from $2.5 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year EBT high stood at $2.5 million for Q2 2025, and its period low was -$24.5 million during Q1 2025.
  • In the last 5 years, Arbutus Biopharma's EBT had a median value of -$17.9 million in 2024 and averaged -$16.5 million.
  • As far as peak fluctuations go, Arbutus Biopharma's EBT crashed by 4432.47% in 2023, and later skyrocketed by 11264.4% in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's EBT stood at -$21.3 million in 2021, then decreased by 2.87% to -$21.9 million in 2022, then increased by 11.95% to -$19.3 million in 2023, then surged by 35.28% to -$12.5 million in 2024, then skyrocketed by 38.16% to -$7.7 million in 2025.
  • Its EBT was -$7.7 million in Q3 2025, compared to $2.5 million in Q2 2025 and -$24.5 million in Q1 2025.